Exploring Advantages to Third-Generation TKIs in Lung Cancer
Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.
Sukhmani Padda, MD, assistant professor of medicine at Stanford University, discusses how third-generation EGFR tyrosine kinase inhibitors (TKIs) compare to the first- and second-generation TKIs.
Osimertinib (Tagrisso) is currently the only approved third-generation TKI, but this agent has dramatically changed the treatment landscape in lung cancer, says Padda.
Unlike earlier generation TKIs, the third-generation TKIs select for activity againstT709M
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
